Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma

Int J Oncol. 2008 Feb;32(2):333-40.

Abstract

A total of 101 primary cervical adenocarcinomas were analyzed for the presence of p16INK4a and MIB-1 expression in correlation with the presence of 'high-risk' types of human papillomavirus (HR-HPV) and clinical outcome. We found that adenocarcinoma grading showed a significant negative correlation to p16INK4a levels (p=0.001): i.e. we found less intense p16 staining in poorly differentiated tumors than in more highly differentiated tumors as well as a highly significant correlation between HPV infection and higher levels of p16INK4a staining (p=0.00), which was similar for different HPV-types. Tumor suppressor protein p16INK4a levels were higher in HPV positive than in HPV negative tumors. Higher levels of the proliferation marker MIB-1 were associated with poorer outcome. Higher MIB-1 levels were seen in tumors with a lower grade and higher stage at diagnosis. Moreover, MIB-1 levels seem to be higher in tumors due to infection with HPV 16 and 18 compared with HPV 45. MIB-1 may be a helpful marker in grading adenocarcinoma: a high level of expression of MIB-1 indicates a low grade of tumor, whereas high expression of p16INK4a indicates a highly differentiated of the tumor. Thus, immunostaining for p16INK4a appears to be a useful diagnostic tool for cervical adenocarcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / complications*
  • Adenocarcinoma / virology*
  • Adult
  • Aged
  • Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis*
  • Disease Progression
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Gene Expression Regulation, Viral*
  • Humans
  • Ki-67 Antigen / biosynthesis*
  • Middle Aged
  • Papillomaviridae / metabolism*
  • Papillomavirus Infections / complications*
  • Treatment Outcome
  • Uterine Cervical Neoplasms / complications*
  • Uterine Cervical Neoplasms / virology*

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • Ki-67 Antigen